CGEN: Rentang target analis Compugen Ltd

Compugen Ltd. (CGEN) is establishing a robust delivery system for biomaterials used in oncology research, minimizing the risk of component shortages to maintain profitability. This chart illustrating the price evolution of the stock captured the value at 4.61. Compugen Ltd. (CGEN) relies on external outsourcing for production and testing to avoid capital expenditures. Stable management under Anat Cohen-Dayag successfully monetizes patents through strategic alliances with industry behemoths.

This indicator represents the weighted average of target prices from leading analysts, filtering out market noise to determine the asset's fundamental value. By analyzing the consolidated target forecast from investment houses, an investor gains an objective assessment of the potential of Compugen Ltd. (CGEN), where the precision of computational algorithms for identifying cancer immunotherapy targets translates directly into experts' long-term expectations for the company's capitalization.